UK's Smith+Nephew keeps outlook, plans share buyback as quarterly revenue rises
Smith+Nephew's Financial Performance and Strategic Initiatives
Quarterly Revenue Growth
May 6 (Reuters) - Medical products maker Smith+Nephew posted higher first-quarter underlying revenue on Wednesday, helped by strong sports medicine and wound management performance, and kept its annual outlook unchanged while unveiling a $500 million share buyback.
Product Segments Driving Growth
The British company, which makes orthopaedic implants, wound dressings, and other surgical aids, is seeking to accelerate growth following a three-year turnaround to counter margin pressure stemming from inflation and supply‑chain disruptions.
Outlook and Analyst Expectations
The company, which reiterated that growth would be weighed towards the second half of the year, posted revenue of $1.5 billion for the quarter ended March 28, with underlying revenue growth of 3.1%. Analysts were expecting a 3.2% rise in a company-compiled poll.
(Reporting by Nithyashree R B in Bengaluru; Editing by Sherry Jacob-Phillips and Subhranshu Sahu)




